Beijing Rain and Earth Technology to provide cheaper blood dialysis in China

RainEarth Inc. (OTC Bulletin Board: RNER; "the Company") announced that in the second quarter of 2009, the Xinhua News Agency publicized the creation of "Opinions of the CPC Central Committee and the State Council on Deepening the Reform of the Medical and Health Care System" ("Opinion").

The "Opinion" proposed practical methods to enable people to go see a doctor more easily. Reduced cost is the short-term goal and the long-term goal is to establish a medical coverage plan for urban and rural populations that meets their basic medical requirements more effectively and conveniently.

The Company's Chinese subsidiary, Beijing Rain and Earth Technology Development Corp. Ltd. ("China RainEarth") not only complied with this system of medical reform, but will also continue improving the quality of its products while keeping prices competitive and affordable for patients.

China RainEarth's main product, blood dialysis, is an effective measure for patients with acute and chronic renal failure (uremia) to sustain their lives. Currently, there are about 60,000 renal failure patients, who spend more than RMB six billion (approximately US$882 Million) every year on blood dialysis in China.

Currently, imported products dominate the market. Comparatively, domestic products only have less than 2% market share. With social and economic development as well as the improvement of healthcare services, 15 million blood dialyzers will be sold in China by 2012 and the market size will hit RMB 1.2 billion (approximately US$176 million). At that time, the market share of domestic products will exceed 50%.

"Our blood dialysis is up to 40% cheaper than other imported dialysis. Of course our dialysis maintains the same high quality," said Yongfu Zhu, CEO of the Company. "Our dialysis has been used by several hospitals and as it is recognized by more patients and hospitals, we will see continued growth for the Company."